InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal

A treatment for a fatal lung-scarring disease — the center of an $8.3 billion buyout of a Peninsula company by drug giant Roche — won regulatory approval Wednesday...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.